{"entity":{"id":"imugene","kind":"company","name":"Imugene","aka":[],"tldr":"Imugene is an Australian company now focused on an off-the-shelf CAR-T cell therapy made from donor cells for people with blood cancers that have come back after other treatments.","summary":"Imugene Limited, headquartered in Sydney and listed on the ASX, describes itself as a clinical-stage cell therapy company developing off-the-shelf cancer treatments. Its lead programme azer-cel (azercabtagene zapreleucel) is an allogeneic CD19-directed CAR-T therapy in a phase 1/1b open-label study in relapsed or refractory non-Hodgkin lymphoma and B cell acute lymphoblastic leukaemia, recruiting in Australia and the United States. The company previously developed oncolytic virus (VAXINIA / CF33, onCARlytics) and B cell vaccine (HER-Vaxx, PD1-Vaxx) programmes, but these are not described on the current website, which centres on azer-cel. No capital raising could be sourced from fetched pages.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Imugene","links":[{"label":"Official website","url":"https://www.imugene.com"},{"label":"Clinical trials","url":"https://imugene.com/pipeline/clinical-trials/"}],"tags":[],"related":[],"cancers":["all-leukemia","dlbcl"],"sections":["cell-therapy"],"technologies":["allogeneic-cell-therapy","car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ASX code IMU (IMU.AX) not confirmed on fetched pages, so ticker omitted. Oncolytic virus and vaccine programmes not visible on the current site; companyType set to cell-therapy to match the current lead. dlbcl used as the closest id for relapsed or refractory non-Hodgkin lymphoma."],"hq":"Sydney","country":"AU","companyType":"cell-therapy","website":"https://www.imugene.com","stage":"public","investors":[],"funding":[]},"route":"/companies/imugene/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}]}}